Sunovion to acquire Elevation Pharma

Thursday, August 30, 2012 01:42 PM

Sunovion Pharmaceuticals, a Marlborough, Mass.-based pharmaceutical company focused on the central nervous system and respiratory disease, has agreed to acquire San Diego-based Elevation Pharmaceuticals, which specializes in the development of new aerosol therapies for patients with respiratory diseases.

The acquisition includes Elevation Pharmaceuticals' EP-101 product, an inhalation solution of a long-acting muscarinic antagonist (LAMA) bronchodilator that is in phase IIb clinical trials for the treatment of patients with moderate to severe chronic obstructive pulmonary disease (COPD).

Sunovion will make an upfront payment of $100 million to the shareholders of Elevation on closing of the acquisition of its shares, and thereafter it will make development milestone payments for EP-101 up to $90 million. Furthermore, after the regulatory approval, Sunovion will also make commercial milestone payments up to $210 million. Subsequent milestone payments up to $30 million could occur contingent upon the successive development of additional new programs.

"Nebulized medicine is an important treatment option for older and sicker patients—the fastest growing segment within COPD," said Bill Gerhart, founder and CEO of Elevation Pharmaceuticals. "Sunovion is the ideal sponsor to realize our original vision to significantly elevate the standard of care for this underserved patient population."

The boards of both Sunovion and Elevation have approved the transaction. The acquisition is subject to customary closing conditions.

Share:          
CWWeekly

June 29

FDA and PatientsLikeMe collaborate to test social media adverse event reporting

Boston-area teaching hospitals launch web portal to attract life science companies

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

July

Integrated research partnerships build momentum
Research function provides infrastructure, leverages large pool of health systems' patients and data

'Right to Try' laws challenge clinical trial process
20 states pass, 20 more pending allowing access to study drugs without FDA and IRB approval

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

June

TransCelerate Biopharma turns three
High-profile consortium has made inroads fixing wasteful practices, but it still has more work ahead

Pharma industry improves its tarnished reputation
Delivering innovation, social responsibility will help rebuild trust

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs